Search Results

LG Chem and AVEO Oncology, an LG Chem company, announced that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109, LG Chem’s first proprietary anti-cancer investigational drug candidate.

The Jackson Laboratory and LG AI Research signed a partnership agreement creating an alliance between JAX’s longstanding expertise in biomedical research and data analysis and LG’s AI research and product development prowess.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a contract research agreement with SEKISUI CHEMICAL CO., LTD..

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced it has entered into a global licensing agreement with LG Chem, Ltd. (“LG Chem”), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.

UroGen Pharma Ltd. announced 82.3% 12-month duration of response data by Kaplan-Meier estimate from its Phase 3 ENVISION trial in patients who achieved complete response at three months after the first instillation of investigational drug UGN-102 for intravesical solution.